Search for a trial

A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM
STUDY OF AVELUMAb (MSB0010718C) IN COMBINATION WITH AXITINIB
(INLYTA®) VERSUS SUNITINIB (SUTENT®) ) MONOTHERAPY IN THE
FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL
CARCINOMA

Primary ObjectiveTo demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS or OS in the first-line treatment of PD-L1 positive patients with aRCC.Secondary Objectives* To demonstrate that…

A phase 3 multicenter, long-term extension study to evaluate the long-term safety and efficacy of Upadacitinib (ABT-494) in subjects with ulcerative colitis (UC).

This study has been transitioned to CTIS with ID 2023-505699-31-00 check the CTIS register for the current data. To evaluate the Long-Term Safety and Efficacy of upadacitinib.